Compare Enveric Biosciences Inc (ENVB) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wynn Resorts, Limited — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Wynn Resorts, Limited trades at $98.6 (market cap $10.07B). The key difference: Wynn Resorts, Limited is far larger — about 1892.9× Enveric Biosciences Inc's market cap, and Wynn Resorts, Limited pays a 1.03% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | WYNN | |
|---|---|---|
Market Cap | $5.32M | $10.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $133.34 |
52-Week Low | $1.28 | $94.78 |
Enterprise Value | $408.82K | $20.44B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Wynn Resorts (WYNN) trades at $95.9, down 1.27% over 24 hours, with a bearish technical signal and recent earnings misses. The company reported Q1 2026 EPS of $1.25, meeting expectations but missing in prior quarters, while revenue growth remains steady at $7.14B in 2025. High debt levels and negative shareholder equity pose fundamental concerns, though analyst sentiment is bullish with a $135 consensus price target.
The stock offers upside potential based on analyst targets but faces headwinds from margin pressure, geopolitical risks in expansion projects, and volatile casino demand. Investment appeal hinges on execution in Macau and Las Vegas, with cash flow stability needed to address leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
